
Methylpiperidino pyrazole
CAS No. 289726-02-9
Methylpiperidino pyrazole( —— )
Catalog No. M27481 CAS No. 289726-02-9
Methylpiperidino pyrazole is an ERα inhibitor and can prevent the BPS-induced Rb phosphorylation and cell cycle progression.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 53 | In Stock |
![]() ![]() |
5MG | 77 | In Stock |
![]() ![]() |
10MG | 143 | In Stock |
![]() ![]() |
25MG | 314 | In Stock |
![]() ![]() |
50MG | 588 | In Stock |
![]() ![]() |
100MG | 881 | In Stock |
![]() ![]() |
200MG | 1322 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMethylpiperidino pyrazole
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethylpiperidino pyrazole is an ERα inhibitor and can prevent the BPS-induced Rb phosphorylation and cell cycle progression.
-
DescriptionMethylpiperidino pyrazole is an ERα inhibitor and can prevent the BPS-induced Rb phosphorylation and cell cycle progression.
-
In VitroMPP (1, 5, 10, 25, 50 and 100 μM; 24 h) decreases cell viability with an IC50 value of 20.01 μM in RL95-2 cells.MPP dihydrochloride shows antiproliferative activity at a concentration of 10 μM inRL95-2 cells.MPP dihydrochloride (20 μM; 24 h) reduces the phosphorylation of ERα, while it does not alter the phosphorylation of Akt. MPP dihydrochloride reduces the ratio of p-ERα/ERα.Cell Viability Assay Cell Line:RL95-2 endometrium cancer cells Concentration:1, 5, 10, 25, 50 and 100 μM Incubation Time:24 hours Result:The treatment with 25 μM, 50 μM and 100 μM for 24 h decreased cell viability significantly. However, cell viability was not significantly changed by MPP dihydrochloride at concentration below 25 μM.Cell Proliferation Assay Cell Line:RL95-2 cell Concentration:10, 15, 20 and 25 μM Incubation Time:72 hours Result:Showed antiproliferative activity at a concentration of 10 μM.Western Blot Analysis Cell Line:RL95-2 cell line Concentration:20 μM Incubation Time:24 hours Result:Reduced the phosphorylation of ERα, while it did not alter the phosphorylation of Akt. Reduced the ratio of p-ERα/ERα compared to the control group.
-
In VivoMPP (Low dose 20 μg/kg body weight or high dose 200 μg/kg body weight) leads to a dose-dependent attenuation of percent prepulse inhibition (PPI). Animal Model:Male C57BL/6N mice at the age of 9-10 weeksDosage:Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight) Administration:Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing Result:Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number289726-02-9
-
Formula Weight469.57
-
Molecular FormulaC29H31N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1c(-c(cc2)ccc2OCCN2CCCCC2)n(-c(cc2)ccc2O)nc1-c(cc1)ccc1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Robinson DM, Keating GM. Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs. 2007;7(6):453-65.
molnova catalog



related products
-
BHPI
BHPI is a potent, noncompetitive small molecule ERα inhibitor.
-
Toremifene citrate
Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.
-
LY88074
LY88074 is a raloxifene analog in which the basic side chain has been removed. LY88074 is an agonist of ERβ (EC50 = 232 nM).This compound stimulates uterine cell proliferation.